Rx Medicare

Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials…

Read More…

Related Posts

• CSL Biotherapies Announces Start Of U.S. H1N1 Vaccine Clinical Trials
• Sinovac Reports Positive Preliminary Results For Clinical Trials Of H1N1 Vaccine
• Swine Flu: NIAID Set To Launch Clinical Trials To Test 2009 H1N1 Influenza Vaccine Candidates
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
• SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine
• US To Start Human Trials Of H1N1 Swine Flu Vaccine In August
• Dynavax Selects Clinical Candidate In Universal Flu Vaccine Program
• FDA Recommends H1N1 For Inclusion In Next Year’s Flu Vaccine
• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine To Biological E.; Vaccine Could Become Available For Use In India This Year
• Canada To Bridge Mexico’s H1N1 Flu Vaccine Requirements
• H1N1 Vaccine Administration Goes Well In Northwest Alabama
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• Scientist Begins To Unravel What Makes Pandemic H1N1 Tick

Tags: begins, bharat, biotech, cell, clinical, culture, efficacy, h1n1, phase, trials, vaccine

This entry was posted on Monday, January 25th, 2010 at 4:01 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.